Author Archives: Maya B

Chemistry for Cancer: New Radioactive Tracers for Cancer Diagnosis

Cutting-edge chemistry may be the key to fast and efficient cancer diagnoses. In early 2020, Antonio Wong and his research team at the University of British Columbia (UBC) in Vancouver, BC, developed a new way to synthesize radioactive tracers for positron emission tomography (PET) scan cancer diagnosis. Recently, I interviewed Antonio to discuss his research.

The Problem 

Imaging technologies like the CT scan, ultrasound, X-ray, MRI, and PET scans allow doctors to identify cancerous masses in patients. Although PET scans are a common way to diagnose cancer, researchers want to find ways to make tracers more efficiently. So, Antonio and his team aimed to develop a new kind of tracer and to make the synthetic process more efficient.

PET scan and technician, Source: http://www.bccancer.bc.ca

The Science 

Since cancer cells divide quickly and uncontrollably, they require many more cellular “building blocks” compared to regular cells. Taking advantage of this, researchers have previously developed “tagged” versions of  these building blocks, called tracers, which accumulate inside cancer cells. This allows doctors to see tumors in PET scan images. When I spoke to Antonio, he explained that the “golden standard” for PET imaging uses a sugar molecule called glucose tagged with a radioactive fluoride atom (called FDG) which is responsible for the glow on medical images. To see how tracers work, check out this video below.

Combining innovation and creativity, Antonio’s team developed a more efficient way to make these tiny building blocks by using a careful mixture of chemicals. They used a molecule called thymidine which is required for cell division, tagged it with a radioactive atom (18F), and injected into mice with cancer. The mice were then put into a PET scan to see if the building blocks were “building up” inside the tumors, which would glow on the PET scan images.

Tracer synthesis, Source: Antonio’s Paper

The Impact 

When Antonio ran this study, he was an undergraduate student at UBC. As a result, his story has caught the attention of students on campus. After my interview with Antonio, my colleague Parwaz, a UBC student who runs a podcast called “Thinkin’ a Latte”, chatted with two other UBC undergraduates about the interview. Check out their podcast below.

Although the study’s findings are promising, using thymidine-based tracers for PET tumor imaging requires much more research before it can be used in clinics. 

“I think the significance of this paper is not like ‘look this is the next blockbuster drug that we’re trying to use’, this is more like a proof of concept”

– Antonio Wong

Nonetheless, cancer is a prevalent disease that has touched the lives of almost everyone and research like Antonio’s is bringing much needed innovation and creativity to the field.

– Maya Bird 

Co-authors: Parwaz, Samin, and Teaya 

Borrowing from Mosquitos – A Potential Broad-Spectrum Antiviral

A team of researchers at the National Institute of Environmental Health Sciences (NIEHS) have found a promising antiviral in the strangest place – a protein called AEG12 found in the gut of mosquitos. This recent study lead by Dr. Alexander Foo found that AEG12 strongly inhibits the family of viruses that cause Yellow Fever, Dengue, West Nile, and Zika, and that the protein may also inhibit their distant relative: coronaviruses. Although the virus-killing AEG12 protein sounds promising, it may still be a long time before its safe to use in humans.

The Aedes aegypti mosquito, which can carry viruses such as Yellow Fever, Dengue, and Zika (Image source)

Foo and His Findings

Scientists have long been on the hunt for effective antivirals, and researchers like Dr. Foo have been making great progress in the field. Foo’s recent study showed that AEG12 was effective at killing flaviviruses (such as Dengue and Zika) but was less effective at killing coronaviruses. Using methods and software tools for understanding how proteins work and specialized laboratory techniques to study viruses, the team was able to piece together how AEG12 is such a successful virus-destroyer.

Flaviviruses are enveloped: meaning that each virus particle is surrounded by a membrane. The infection process, in the video below, shows how the virus must first attach to the surface a human cell (0:28) and then fuse its membrane with ours to get inside (1:12).

Essentially, the AEG12 protein carries little membrane pieces of its own, which are different from the type found in the virus’ membrane. When it comes across a virus, AEG12 trades its pieces for the virus’. Once enough chunks are swapped out, the virus’ membrane becomes unstable and can’t fuse with our cells: effectively “killing” the virus.

The AEG12 protein swaps out viral membrane pieces for unstable pieces (Image source)

Even though AEG12’s virus-killing abilities sound promising, Foo’s team found that AEG12 breaks apart red blood cells. Although useful to a mosquito that needs to digest a blood meal, use of AEG12 in humans would lead to a very serious blood disorder that could be fatal if left untreated.

There is Still Hope

So, AEG12 isn’t safe for use in humans… Yet. With some clever solutions and careful bioengineering, further research could find a way to modify AEG12 so that it targets viruses and ignores human cells. The development of a drug or molecule effective against enveloped viruses could save lives across the globe – addressing not only the headlining COVID-19 pandemic, but the ongoing epidemics as well.

-Maya Bird

From Recreational to Pharmaceutical – A Promising Psychedelic in Research

Current research on the use of psychedelic drugs for therapeutic applications is showing a lot of promise, building on the potential first demonstrated by studies  conducted in the 1950’s. Humphry Osmond, the psychiatrist who coined the term “psychedelics”, is considered one of the pioneers of psychedelics research. He believed hallucinogenic drugs could be used to treat mental illnesses, and his research findings supported his beliefs. His study on the use of LSD to treat alcoholism found that at the one year follow-up, almost half of study participants who suffered from alcoholism didn’t return to drinking. As such, Osmond’s seminal studies paved the path for the emerging field of psychedelics research. Fast-forward to today, research studies are demonstrating that under controlled conditions, psychedelic drugs like LSD, psilocybin (the active compound in magic mushrooms), and ketamine hold the potential for treating an array of mental illnesses – from alcoholism, to PTSD, to depression, anxiety, and OCD.  As the newest addition, MDMA is joining the rest of its peers in psychedelics research and may hold great potential.

Humphry Osmond, Source: Jeremy Leung

MDMA, otherwise known as ecstasy, E, M, or Molly, is an infamous psychoactive drug often associated with nightclub and rave scenes. Hours of partying are fueled by intense feelings of pleasure, emotional warmth, and an abundance of energy owed to this little pill with so many names. The negative stigma attached to recreational drug use has given MDMA a bad rep, but research studies from an organization called Multidisciplinary Association for Psychedelics Studies (MAPS) are challenging these stigmatized views.

A team of MAPS researchers in California are repurposing MDMA to treat the psychological distress experienced by people suffering from life-threatening illnesses (LTI). People living with, or that have lived with an LTI can experience anxiety, depression, anger, and despair associated with their traumatic experiences. In one of the first clinical trials of its kind, Dr. Philip Wolfson and his team explored how using MDMA during psychotherapy sessions impacted participant’s distress levels. The team found that the study participants who took MDMA had improved mindfulness and a more positive outlook towards their traumatic experiences. Also, depression, sleep quality, and anxiety levels  improved, but these improvements couldn’t conclusively be attributed to the MDMA. The findings of this pilot study suggest MDMA could still have the potential to reduce psychological distress associated with LTI and that it may also have positive long-term effects.

Although current studies like Dr. Wolfson’s show promising results, could the stigma surrounding “hard drugs” like MDMA deter patients from taking them once/if they become approved for clinical use? Or would the existing stigma dwindle once they get a doctor’s stamp of approval? Or maybe it’s simply why the drugs are used that give recreational use a bad name. Whatever your beliefs and convictions, scientifically, “hard drugs” may have a place in medicine in the (potentially near) future.

Source: GoodRx.com

By Maya Bird

From Recreational to Pharmaceutical – Promising Party Drugs in Research

Source: Unsplash.com

3,4-Methylenedioxymethamphetamine, more commonly known as MDMA, ecstasy, E, M, or Molly, is an infamous psychoactive drug often associated with nightclub and rave scenes. Hours of partying are fueled by intense feelings of pleasure, emotional warmth, and an abundance of energy owed to this little pill with so many names. The negative stigma attached to recreational drug use has given MDMA a bad rep, but a team of researchers in California are repurposing this synthetic drug to treat anxiety in people suffering from life-threatening illnesses (LTI).

In one of the first clinical trials of its kind, Dr. Philip Wolfson and his team explored how using MDMA during psychotherapy sessions impacted anxiety levels. The team found that the study participants who took MDMA had improved mindfulness and a more positive outlook towards their traumatic experiences. Depression, sleep quality, and anxiety levels also improved, but these improvements couldn’t conclusively be attributed to the MDMA. The findings of this small pilot study suggest MDMA could still have potential to reduce anxiety associated with LTI and may also have positive long-term effects.

MDMA is only one of many drugs currently being researched for therapeutic applications. LSD, famously tested for mind control by the CIA in the 1950’s and 60’s as a part of the MK-ULTRA Program, shows potential for treating alcoholism and could also treat PTSD. Another psychedelic drug called psilocybin, the active compound in magic mushrooms, is being investigated to treat a myriad of mental health disorders: from depression, to anxiety, to OCD, to certain substance use disorders. A horse tranquillizer called ketamine, which doubles as a club drug, is being researched to treat depression and (so far) shows potential.

Although current studies show promising results, could the stigma surrounding hard drugs like MDMA and ketamine deter patients from taking them once/if they become approved for clinical use? Or would the existing stigma dwindle once they get a doctor’s stamp of approval? Or maybe it’s simply why the drugs are used that give recreational use a bad name. Whatever your beliefs and convictions, scientifically, hard drugs may have a place in medicine in the (potentially near) future.

Source: GoodRx.com

By Maya Bird